Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Goldman Sachs: Bullish on Gold, Predicts Price Will Hit $4900 by 2026

Goldman Sachs: Bullish on Gold, Predicts Price Will Hit $4900 by 2026

BlockBeatsBlockBeats2025/12/19 08:39

BlockBeats News, December 19th - In its latest 2025-2026 Commodities Outlook report, Goldman Sachs stated that 2026 will be the final year of global oil supply volatility. The market is expected to see an average daily oversupply of 2 million barrels, causing the price of Brent crude to drop to an average of $56 per barrel in 2026 and hit bottom in the middle of the year.


Furthermore, Goldman Sachs reiterated its forecast for a gold price increase to $4900 in 2026. It believes that global central bank gold purchases and Fed rate cuts will be dual drivers of the price increase. The analysis points out that geopolitical risks and economic uncertainties are prompting emerging market central banks to accelerate their gold holdings, while the potential entry of private investors may further drive up the price of gold. Goldman Sachs expects global central banks to maintain a monthly gold purchase volume of around 70 tons in 2026, and for every 1 basis point increase in the allocation of private investors, the gold price is expected to rise by approximately 1.4%.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11

SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.

The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).

智通财经2026/09/22 07:11